Dianthus Therapeutics slips premarket after increased $625 mln share sale

Jefferies Financial

11/03/2026 12:15

** Dianthus Therapeutics DNTH.O shares down 1.6% at $85.52 premarket after above-target equity raise

** Biotech firm late Tues announced ~7.7 mln shares, including pre-funded warrants to buy 402,468 shares, at $81 for $625 mln gross raise

** Offering priced at 6.8% discount to stock's last sale of $86.92 on Tues

** DNTH shares jumped 21.5% on Mon after its nerve disease drug showed faster‑than‑expected response in late-stage trial

** Shares on Tues added another 9.7% after co late Mon started $400 mln offering to advance clinical and preclinical development activities, commercial readiness activities and for other purposes

** Jefferies, TD Cowen, Evercore, Stifel, Guggenheim and William Blair joint bookrunners for offering

** Through Tues, shares up 111% YTD. They closed at $23.38 a year ago

** Avg rating of 15 analysts is "strong buy"; median PT of $124 implies ~43% upside to last close, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))